Patents by Inventor David Bogucki
David Bogucki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220409589Abstract: The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).Type: ApplicationFiled: January 13, 2022Publication date: December 29, 2022Inventors: Gary J. Bridger, Renato T. Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason B. Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria Rosaria Di Fluri
-
Publication number: 20200000774Abstract: The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).Type: ApplicationFiled: April 10, 2019Publication date: January 2, 2020Inventors: Gary J. Bridger, Renato T. Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason B. Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria Rosaria Di Fluri
-
Patent number: 10272081Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: GrantFiled: January 30, 2018Date of Patent: April 30, 2019Assignee: Aquinox Pharmaceuticals (Canada) Inc.Inventors: Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew, Vladimir Khlebnikov, Rudong Shan
-
Publication number: 20190023709Abstract: Compounds of formula (I): where R1, R2, R3, R4a, R4b, R5, R6 and R7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: September 12, 2018Publication date: January 24, 2019Inventors: Lloyd F. Mackenzie, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew
-
Patent number: 10174046Abstract: Compounds of formula (II): wherein R1, R2, R5 and R13 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds have activity as SHIP1 modulators, and thus may be useful in treating a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of the invention are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: GrantFiled: August 14, 2017Date of Patent: January 8, 2019Assignee: Aquinox Pharmaceuticals (Canada) Inc.Inventors: Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew
-
Publication number: 20180360828Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: January 30, 2018Publication date: December 20, 2018Inventors: Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew, Vladimir Khlebnikov, Rudong Shan
-
Patent number: 10100056Abstract: Compounds of formula (I): where R1, R2, R3, R4a, R4b, R5, R6 and R7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: GrantFiled: February 27, 2014Date of Patent: October 16, 2018Assignee: Aquinox Pharmaceuticals (Canada) Inc.Inventors: Lloyd F. Mackenzie, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew
-
Publication number: 20180161324Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: January 30, 2018Publication date: June 14, 2018Inventors: Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew, Vladimir Khlebnikov, Rudong Shan
-
Publication number: 20180155359Abstract: Compounds of formula (II): wherein R1, R2, R5 and R13 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds have activity as SHIP1 modulators, and thus may be useful in treating a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of the invention are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: August 14, 2017Publication date: June 7, 2018Inventors: Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew
-
Patent number: 9937167Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: GrantFiled: December 6, 2016Date of Patent: April 10, 2018Assignee: Aquinox Pharmaceuticals (Canada) Inc.Inventors: Lloyd F. Mackenzie, Thomas B. Macrury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew, Vladimir Khlebnikov, Rudong Shan
-
Publication number: 20170362250Abstract: Compounds of formula (II): wherein R1, R2, R5 and R13 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds have activity as SHIP1 modulators, and thus may be useful in treating a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of the invention are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: August 14, 2017Publication date: December 21, 2017Inventors: Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew
-
Patent number: 9765085Abstract: Compounds of formula (II): wherein A, R1, R2, R5 and R13 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds have activity as SHIP1 modulators, and thus may be useful in treating a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of the invention are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: GrantFiled: February 27, 2014Date of Patent: September 19, 2017Assignee: Aquinox Pharmaceuticals (Canada) Inc.Inventors: Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew
-
Publication number: 20170253596Abstract: Compounds of formula (I): where R1, R2, R3, R4a, R4b, R5, R6 and R7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: February 27, 2014Publication date: September 7, 2017Inventors: Lloyd F. Mackenzie, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew
-
Publication number: 20170247389Abstract: Compounds of formula (II): wherein R1, R2, R5 and R13 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds have activity as SHIP1 modulators, and thus may be useful in treating a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of the invention are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: February 27, 2014Publication date: August 31, 2017Inventors: Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew
-
Publication number: 20170224682Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: December 6, 2016Publication date: August 10, 2017Inventors: Lloyd F. MACKENZIE, Thomas B. MACRURY, Curtis HARWIG, David BOGUCKI, Jeffery R. RAYMOND, Jeremy D. PETTIGREW, Vladimir KHLEBNIKOV, Rudong SHAN
-
Patent number: 9540353Abstract: Compounds of formula (I): where, n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: GrantFiled: January 7, 2014Date of Patent: January 10, 2017Assignee: Aquinox Pharmaceuticals (Canada) Inc.Inventors: Lloyd F. Mackenzie, Thomas B. Macrury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew, Vladimir Khlebnikov, Rudong Shan
-
Publication number: 20160257671Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: January 7, 2014Publication date: September 8, 2016Inventors: Lloyd F. MACKENZIE, Thomas B. MACRURY, Curtis HARWIG, David BOGUCKI, Jeffery R. RAYMOND, Jeremy D. PETTIGREW, Vladimir KHLEBNIKOV, Rudong SHAN
-
Publication number: 20160083387Abstract: Compounds of formula (I): where R1, R2, R3, R4a, R4b, R5, R6 and R7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: February 27, 2014Publication date: March 24, 2016Inventors: Lloyd F. Mackenzie, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew
-
Publication number: 20160031899Abstract: Compounds of formula (II): wherein A, R1, R2, R5 and R13 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds have activity as SHIP1 modulators, and thus may be useful in treating a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of the invention are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: February 27, 2014Publication date: February 4, 2016Inventors: Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew
-
Publication number: 20150336935Abstract: Compounds of formula (I): where, n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: January 7, 2014Publication date: November 26, 2015Inventors: Lloyd F. MACKENZIE, Thomas B. MACRURY, Curtis HARWIG, David BOGUCKI, Jeffery R. RAYMOND, Jeremy D. PETTIGREW, Vladimir KHLEBNIKOV, Rudong SHAN